» Articles » PMID: 15494428

Human Mesenchymal Stem Cells Modulate Allogeneic Immune Cell Responses

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2004 Oct 21
PMID 15494428
Citations 1725
Authors
Affiliations
Soon will be listed here.
Abstract

Mesenchymal stem cells (MSCs) are multipotent cells found in several adult tissues. Transplanted allogeneic MSCs can be detected in recipients at extended time points, indicating a lack of immune recognition and clearance. As well, a role for bone marrow-derived MSCs in reducing the incidence and severity of graft-versus-host disease (GVHD) during allogeneic transplantation has recently been reported; however, the mechanisms remain to be investigated. We examined the immunomodulatory functions of human MSCs (hMSCs) by coculturing them with purified subpopulations of immune cells and report here that hMSCs altered the cytokine secretion profile of dendritic cells (DCs), naive and effector T cells (T helper 1 [T(H)1] and T(H)2), and natural killer (NK) cells to induce a more anti-inflammatory or tolerant phenotype. Specifically, the hMSCs caused mature DCs type 1 (DC1) to decrease tumor necrosis factor alpha (TNF-alpha) secretion and mature DC2 to increase interleukin-10 (IL-10) secretion; hMSCs caused T(H)1 cells to decrease interferon gamma (IFN-gamma) and caused the T(H)2 cells to increase secretion of IL-4; hMSCs caused an increase in the proportion of regulatory T cells (T(Regs)) present; and hMSCs decreased secretion of IFN-gamma from the NK cells. Mechanistically, the hMSCs produced elevated prostaglandin E2 (PGE(2)) in co-cultures, and inhibitors of PGE(2) production mitigated hMSC-mediated immune modulation. These data offer insight into the interactions between allogeneic MSCs and immune cells and provide mechanisms likely involved with the in vivo MSC-mediated induction of tolerance that could be therapeutic for reduction of GVHD, rejection, and modulation of inflammation.

Citing Articles

A Systematic Review of Regenerative Medicine Therapies for Axial Spine Pain of Facet Joint Origin.

Manchikanti L, Abd-Elsayed A, Kaye A, Sanapati M, Pampati V, Shekoohi S Curr Pain Headache Rep. 2025; 29(1):61.

PMID: 40085275 DOI: 10.1007/s11916-025-01376-1.


Mesenchymal Stem Cell-Derived Exosome miR-153-3 Induced M2-Type Polarization of Macrophages to Improve the Healing Effect of Burn Wounds.

Huang C, Lu G, Jia Z, Yan J Appl Biochem Biotechnol. 2025; .

PMID: 40053206 DOI: 10.1007/s12010-025-05196-2.


Mesenchymal stem cells alleviate idiopathic pneumonia syndrome by facilitating M2 polarization via CCL2/CCR2 axis and further inducing formation of regulatory CCR2 + CD4 + T cells.

Xue C, Liu W, Li Y, Yin Y, Tang B, Zhu J Stem Cell Res Ther. 2025; 16(1):108.

PMID: 40025564 PMC: 11872334. DOI: 10.1186/s13287-025-04232-6.


Apoptotic vesicles derived from bone marrow mesenchymal stem cells increase angiogenesis in a hind limb ischemia model via the NAMPT/SIRT1/FOXO1 axis.

Chen J, Shen Z, Chen B, Liu S, Mei Y, Li K Stem Cell Res Ther. 2025; 16(1):105.

PMID: 40025506 PMC: 11872336. DOI: 10.1186/s13287-025-04245-1.


The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party.

Daenen L, van der Wagen L, Bonneville E, Lopez-Corral L, Bukauskas A, Bornhauser M Bone Marrow Transplant. 2025; .

PMID: 39979522 DOI: 10.1038/s41409-025-02531-3.